老年早期乳腺癌患者中曲妥珠单抗为基础化疗方案的毒性及有效性比较
该研究利用2005至2013年SEER-Medicare数据,在65岁以上人表皮生长因子受体2阳性早期乳腺癌患者中比较多柔比星、环磷酰胺、紫杉醇联合曲妥珠单抗(ACTH)与多西他赛、卡铂联合曲妥珠单抗(TCH)的毒性相关住院、生存及曲妥珠单抗完成情况,倾向评分匹配后纳入416例,未发现两组严重不良事件或住院率差异,但TCH组曲妥珠单抗完成率更高,5年生存无差异。
要点
- 倾向评分匹配后,ACTH组与TCH组化疗相关不良事件住院率分别为34%与36.5%,差异无统计学意义(P=.46)。
- TCH组曲妥珠单抗完成率显著高于ACTH组(89% vs 77%,P=.001)。
- 5年乳腺癌特异性生存ACTH组92% vs TCH组96%,风险比2.08(95%CI 0.90-4.82),未达统计学显著。
核心结论
- 在老年匹配样本中,ACTH相比TCH未伴随更高的严重不良事件或住院率,但与辅助曲妥珠单抗完成率较低相关;未检测到5年生存差异。
研究设计与样本
- 利用2005至2013年SEER-Medicare数据,比较65岁以上早期乳腺癌患者接受ACTH与TCH的结局。
- 采用倾向评分匹配平衡两组特征,共分析1077例接受ACTH或TCH的患者,匹配子样本包括416例女性。
主要发现
- 随时间推移TCH使用显著增加,2005年88%患者接受ACTH,到2011年降至15%。
- 匹配患者中,总体医疗使用或化疗相关不良事件无差异(ACTH 34% vs TCH 36.5%;P=.46)。
- TCH组曲妥珠单抗完成率显著更高(89% vs 77%;P=.001)。
- 5年乳腺癌特异性生存无差异(ACTH 92% vs TCH 96%;风险比2.08;95%CI 0.90-4.82),总生存亦无差异。
临床怎么用
- 作者认为,在老年患者证据有限的情况下,基于对毒性或疗效差异的担忧来选择这两种方案可能并不合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The combination of chemotherapy and trastuzumab is the standard of care for adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer. Two regimens have been widely adopted in the United States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCH). No head-to-head comparison of these regimens has been conducted in a clinical trial, and existing trial data have limited generalizability to older patients. Methods We used SEER-Medicare data from 2005 to 2013 to compare outcomes of ACTH versus TCH among patients age older than 65 years. Propensity score matching was used to balance cohort characteristics between treatment arms. Outcomes included toxicity-related hospitalization, survival, and trastuzumab completion. Data from 1,077 patients receiving ACTH or TCH were analyzed, and the propensity-matched subsample included 416 women. Results There was a significant shift toward TCH over time, with 88% of patients receiving ACTH in 2005 compared with 15% by 2011. Among propensity score-matched patients, we found no difference between regimens in health care use overall or for chemotherapy-related adverse events (ACTH, 34% v TCH, 36.5%; P = .46). Patients receiving TCH were significantly more likely to complete trastuzumab (89% v 77%; P = .001). There was no difference in 5-year breast cancer-specific survival (ACTH, 92% v TCH, 96%; hazard ratio, 2.08; 95% CI, 0.90 to 4.82) or overall survival. Conclusion Among a matched sample of older patients, ACTH compared with TCH was not associated with a higher rate of serious adverse events or hospitalizations, but it was associated with less completion of adjuvant trastuzumab. We did not detect a difference in 5-year survival outcomes for ACTH compared with TCH. In the context of limited evidence in older patients, selection between these two regimens on the basis of concerns about differential toxicity or efficacy may not be appropriate.
引用
- Reeder-Hayes KE, Meyer AM, Hinton SP, et al. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. J Clin Oncol. 2017. PMID: 28727517. doi:10.1200/JCO.2016.71.4345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。